Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NS-136
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
NeuShen Initiates First-in-Human Trial of NS-136 for Schizophrenia Treatment
Details : NS-136 is a novel selective M4 receptor positive allosteric modulator (M4 PAM) designed for the treatment of schizophrenia and other conditions associated with psychosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 08, 2024
Lead Product(s) : NS-136
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NS-136
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
First-into-human Study of NS-136 in Healthy Subjects
Details : NS-136 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2024
Lead Product(s) : NS-136
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
NeuShen Therapeutics Closes Pre-A Financing with ~$20M
Details : The successful completion of this fundraising is a testimony to team's ability to accomplish CNS drug development and jump starts the discovery engine to build a pipeline with AAV-based gene therapy and small molecule programs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 29, 2022
Reset All
